With a $1.8 billion purchase with CinCor, AstraZeneca grows its heart and kidney businesses.

9 January (Reuters) AstraZeneca (AZN.L) declared on Monday that it has reached an agreement to acquire American drug-development company CinCor Pharma Inc (CINC.O) for up to $1.8 billion in order to expand its supply of heart and kidney medications.

The experimental medication baxdrostat, which is being developed by CinCor to treat illnesses like high blood pressure and chronic renal disease, is at the heart of the agreement.

Read More

Enjoy this blog? Please spread the word :)

Follow by Email
Runway – mjm news. To succeed in diplomacy, we must tame pro china lobby by. Situated in 19 acres of private woodland, nuffield health ipswich hospital is a unique and tranquil healthcare facility.